|
Market-Based Licensing For HPV Vaccines In Developing Countries
Kevin Outterson and
Aaron S. Kesselheim
Human papillomavirus (HPV) vaccines hold great promise for preventing cervical cancer, but 93 percent of mortality worldwide occurs in low- and middle-income countries, where high vaccine costs can restrict dissemination. Current models for promoting international access to health care innovations include differential pricing, advance market commitments, and voluntary and compulsory licensing. Some of these mechanisms have been effective, but much room for improvement remains. We discuss the usefulness of a new type of license that uses market forces to lower prices through generic competition in low- and middle-income countries while ensuring that pharmaceutical companies are appropriately reimbursed for their research and development.

What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Amin, R. Rajkumar, P. Radhakrishnan, and A. S. Kesselheim
Expert Review Of Drug Patent Applications: Improving Health In The Developing World
Health Aff.,
September 1, 2009;
28(5):
w948 - w956.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Reichman
Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options
J. Law Med. Ethics,
June 1, 2009;
37(2):
247 - 263.
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Kesselheim
Drug Development for Neglected Diseases -- The Trouble with FDA Review Vouchers
N. Engl. J. Med.,
November 6, 2008;
359(19):
1981 - 1983.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A Chokshi and A. S Kesselheim
Rethinking global access to vaccines
BMJ,
April 5, 2008;
336(7647):
750 - 753.
[Full Text]
[PDF]
|
 |
|
Comments:
Read all Comments
- Feasibility of GO (Generic Open) License
- Manthan D. Janodia, et al.
- Health Affairs, 16 Jan 2008
[Full text]
|